Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
59.1M
-
Shares change
-
+3.53M
-
Total reported value, excl. options
-
$1.02B
-
Value change
-
+$65.5M
-
Put/Call ratio
-
0.9
-
Number of buys
-
44
-
Number of sells
-
-68
-
Price
-
$17.24
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2022
138 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q1 2022.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.1M shares
of 108M outstanding shares and own 54.56% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5.73M shares), VR Adviser, LLC (4.56M shares), BlackRock Inc. (3.99M shares), BVF INC/IL (3.98M shares), Rock Springs Capital Management LP (3.87M shares), Foresite Capital Management IV, LLC (2.9M shares), VANGUARD GROUP INC (2.73M shares), COMMODORE CAPITAL LP (2.31M shares), Point72 Asset Management, L.P. (2.28M shares), and Holocene Advisors, LP (2.06M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.